3B Blackbio Dx Limited (3BBLACKBIO) fundamentals
3B Blackbio Dx Limited is a listed company in Healthcare Services, part of the Healthcare sector, listed on the NSE as 3BBLACKBIO (ISIN INE994E01018). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What 3B Blackbio Dx Limited does
3B Blackbio DX Limited is an India-based company, which is engaged in the field of polymerase chain reaction (PCR)-based Molecular Diagnostic Kits. Its segments include Agrochemicals and Diagnostic kits. The diagnostics division of the Company is engaged in Design, Development Manufacturing and Commercialization of qPCR tests, Rapid tests, Next Gen Sequencing (NGS)-based Molecular Diagnostic Kits and Extraction Kits for reliable testing on patient samples. Its products include Oncology and Hematology, Antimicrobial Resistance, Infectious Diseases, Human Genetics, Extraction, and Rapid Antigen Kits. The PCR-based Molecular Diagnostic Kits are commercialized with TRUPCR brand to renowned diagnostics labs across the country. The Company also has a Lateral Flow Assays Vertical and a NGS Assay development division. The lateral flow assays are commercialized under the brand name TRURAPID and the NGS assays are commercialized under the brand name TRUNGS.
Valuation and market data
| Last close | ₹1420.00 |
|---|---|
| Market capitalisation | ₹1,217 crore |
| Enterprise value | ₹1,154 crore |
| P/E (TTM) | 0.00 |
| Price to book | 4.49 |
| Price to sales (TTM) | 6.74 |
| Book value per share | ₹316.29 |
| Dividend yield | 28.17% |
| Sector | Healthcare |
| Industry | Healthcare Services |
| Listed since | Mon Apr 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹111 crore | ₹66 crore | ₹49 crore | 0.00 |
| Mar 2025 | ₹106 crore | ₹64 crore | ₹48 crore | 55.51 |
| Mar 2024 | ₹83 crore | ₹46 crore | ₹34 crore | 39.93 |
| Mar 2023 | ₹67 crore | ₹36 crore | ₹26 crore | 30.85 |
| Mar 2022 | ₹26 crore | ₹8 crore | ₹8 crore | 10.69 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 41.0% |
|---|---|
| Foreign institutions (FII) | 2.5% |
| Mutual funds | 0.0% |
| Other domestic institutions | 2.1% |
| Retail and others | 54.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.